Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477412 · ClinicalTrials.gov registry record · Phase 1
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT00477412: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00477412 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477412, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of bortezomib when given with rituximab and chemotherapy drugs and to see how well they work in treating participants with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, dexamethasone, methotrexate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bortezomib, rituximab and combination chemotherapy may work better at treating mantle cell lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Cytarabine
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2007-04-03 |
| Est. Completion | 2020-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477412
The ClinicalTrials.gov registry entry for NCT00477412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00477412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477412 about?
NCT00477412 is a clinical study titled "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma". This phase I/II trial studies the side effects and best dose of bortezomib when given with rituximab and chemotherapy drugs and to see how well they work in treating participants with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell...
What is the current status of trial NCT00477412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2007-04-03. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT00477412?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Dexamethasone (DRUG), Cytarabine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00477412?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.